Abstract 51P
Background
Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13. Fractionations to investigate early and four year late side effects of hypofractionated postmastectomy radiation therapy (HFRT-PM) of 39 Gy in 13 fractions over 3 weeks.
Methods
We retrospectively analyzed characteristics and outcomes of patients with stage II to III breast cancer treated with HFRT-PM between February 2019 and February 2023 during the COVID-19 pandemic. The selected patients did not have any previously diagnosed heart or lung disease. Treatment provided in 13 fractions of 3 Gy per fraction. The treatment techniques were applied by using 3-dimensional conformal radiation therapy and IMRT of the chest wall with regional nodal volume if required. The end point was freedom from any grade 3 or higher toxicities.
Results
We identified 730 patients with a median follow-up of 4 year. About two-third of the patient (66.6%) had the disease located in the left side. Regional nodal irradiation was done in 84.1% of patients. In multivariate analysis, regional lymph node involvement (≥4 nodes) was associated with worse locoregional control (hazard ratio, 1.68; 95% confidence interval, 1.06-2.67; P = .03) and overall survival (hazard ratio, 2.16; 95% confidence interval, 1.59-2.95; P < .001). The toxicities were acceptable. After a four-year follow -up, there are no grade 3 or 4 toxicities. The incidence of early skin reactions (13% grade 2) cardiac disorders (1.5%), and symptomatic lung fibrosis (1.7%) was low during follow-up. The cumulative rate of arm lymphedema was 2.1% and considered severe in 40 patients (0.05%).
Conclusions
The early results of this study show that HFRT-PM of 39 Gy in 13 fractions over 3 weeks seems safe, but long-term results need to be observed and highlighting the need for long-term follow-up and for randomized trials for hypofractionated radiation therapy postmastectomy especially for young patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract